The invention relates to a stable injectable aqueous solution containing diclofenac and thiocolchicoside, or pharmaceutically acceptable salts thereof, and use thereof in the treatment of painful and inflammatory rheumatic or traumatic conditions of the joints, muscles, tendons and ligaments.
STABLE INJECTABLE COMPOSITION CONTAINING DICLOFENAC AND THIOCOLCHICOSIDE

The present invention relates to a stable injectable composition containing diclofenac and thiocolchicoside, or pharmaceutically acceptable salts thereof, and its use in the treatment of painful and inflammatory rheumatic or traumatic conditions of the joints, muscles, tendons and ligaments.

BACKGROUND TO THE INVENTION

Diclofenac (2-(2-[2,6-dichlorophenylamino]phenyl)acetic acid) is one of the most widely used non-steroidal anti-inflammatory drugs due to its marked pharmacological activity.

A number of formulations of diclofenac for parenteral administration are known, wherein it is present, for example, as a sodium, potassium, diethylamine or 2-hydroxyethylpyrrolidine salt.

Parenteral formulations of diclofenac, in particular of its sodium salt, are disclosed, for example, in US 471 1906.

Thiocolchicoside, also known as 3-demethyl-thiocolchicine glucoside, is a glucoside extracted from the seeds of Colchicum autumnale, which possesses a muscle-relaxant, anti-inflammatory, analgesic and anaesthetic action. It is frequently administered in combination with other medicaments, such as anti-inflammatory agents.

Patent application PCT/TR2009/000137 discloses pharmaceutical compositions containing thiocolchicoside and a non-steroidal anti-inflammatory drug. The compositions can take the form of an aqueous or non-aqueous solution suitable for intravenous, intramuscular or subcutaneous injection.

Pharmaceutical compositions in solid form containing a diclofenac salt and thiocolchicoside are disclosed in EP 0837684A1 (equivalent to FR2735369).

Patent application PCT/EP20 12/06 1468 discloses a patch for transdermal
release, containing diclofenac or a pharmaceutically acceptable salt thereof and thiocolchicoside.

WO2012/053012 discloses a topical composition in the form of a nanoemulsion comprising diclofenac sodium salt and thiocolchicoside.

Pharmaceutical compositions containing 25 or 75 mg of diclofenac sodium salt and 2 or 4 mg of thiocolchicoside in the form of an injectable solution are described in Minerva Anestesiologica, October 1991, pages 1084-1085 and in Bollettino Chimico Farmaceutico 1993, 132/6, pages 203-209. They are a combination of two separate preparations of diclofenac and thiocolchicoside useful for extemporaneous administration. Said extemporaneous injectable solutions are not proprietary medicaments properly so called, as in practice they are prepared at the time of use, and consequently lack long-term stability data.

The availability of a novel association between diclofenac and thiocolchicoside simultaneously present in a pharmaceutical form which presents as a stable injectable preparation in the terms required by the health authorities is therefore of great interest.

The prior art demonstrates that diclofenac is a substance which is relatively unstable in solution, and that the liquid formulations of said substance therefore require the presence of a stabilising agent. The above-mentioned patent US 471 1906 discloses stable aqueous solutions of diclofenac containing a mixture of propylene glycol and polyethylene glycol. The chemical stability of said solutions is obtained by adding a reducing agent which can be a sulphite, such as sodium bisulphite, cysteine and/or cysteine hydrochloride, acetylcysteine and/or acetylcysteine hydrochloride, or a thiosulphate. Their chemical stability is further improved by the presence of lidocaine in addition to the reducing agent.

When preparing a liquid composition containing diclofenac and thiocolchicoside, the inventors of the present application have found that it is necessary to overcome a number of technological difficulties, the most important
requirement being to prevent the degradation of one or both of the active ingredients when formulated in a single unit dose solution.

The antioxidant most widely used to stabilise diclofenac in liquid solutions is sodium bisulphite. There are numerous formulations on the market containing this antioxidant. Other antioxidants used are cysteine, acetylcysteine and reduced glutathione.

Thiocolchicoside also presents stability problems in solution. The chemical and physical compatibility of thiocolchicoside with other injectable medicaments frequently combined with it, including anti-inflammatories, is described in Farmaco, 2002, 57(11), 925-930.

The authors of the present invention have found that the addition of thiocolchicoside to a formulation containing diclofenac makes the use of the above-mentioned antioxidants problematic, if not impossible, as their presence in the solution causes significant degradation of thiocolchicoside and diclofenac under ambient and supra-ambient storage conditions (40°C). As the number of antioxidants suitable for parenteral/injectable use is limited, the impossibility of using said stabilizing agents makes it very complex to obtain formulations which are potentially stable under the conditions required by the health authorities when the product is registered.

Tert-butyl-4-hydroxyanisole, also known as butylated hydroxyanisole or BHA, is an antioxidant widely used in the food and pharmaceutical industry. It is used in fats and oils, foods containing fats, essential oils, and food packaging materials. BHA is a mixture of two isomers: 2-tert-butyl-4-hydroxyanisole (2-BHA) and 3-tert-butyl-4-hydroxyanisole (3-BHA). The two BHA isomers are phenols and therefore react rapidly with free radicals, thus protecting the foods to which they are added against oxidation and alteration of their organoleptic characteristics (colour, odour, flavour and texture).
DESCRIPTION OF THE INVENTION

The object of the present invention is a stable pharmaceutical composition in the form of an injectable aqueous solution containing diclofenac and thiocolchicoside or a pharmaceutically acceptable salt thereof. The present invention solves the technical problem of the instability of liquid formulations containing a combination of diclofenac and thiocolchicoside.

DETAILED DESCRIPTION OF THE INVENTION

The composition of the invention contains tert-butyl 4-hydroxyanisole (BHA) as antioxidant.

Diclofenac is preferably present in the composition as sodium, potassium, calcium or ammonium salt. Diclofenac sodium salt is particularly preferred.

The composition of the invention can optionally also contain excipients suitable for pharmaceutical use, such as mannitol and sorbitol, and can also contain a local anaesthetic, such as lidocaine.

The composition according to the invention can also contain solubilising agents, chelating agents, buffering agents or pH correctors, such as sodium or potassium hydroxide, sodium bicarbonate, tromethamine, monoethanolamine or other organic bases.

In one embodiment of the invention the composition takes the form of an aqueous solution consisting of a mixture of water and propylene glycol.

In a preferred embodiment of the invention the composition takes the form of an aqueous solution containing propylene glycol and diclofenac sodium salt.

Diclofenac sodium salt is preferably present in the composition in quantities ranging from 25 to 75 mg per unit dose administered.

Thiocolchicoside can be present in the composition in quantities ranging from 1 to 10 mg per unit dose administered.

BHA can be present in the composition in quantities ranging from 0.1 to 1.2 mg per unit dose administered.
The excipients mannitol or sorbitol can be present in the composition in quantities ranging from 6 to 32 mg per unit dose administered.

Propylene glycol can be present in the composition in quantities ranging from 800 to 2000 mg per dosage unit.

In a preferred embodiment of the invention the composition contains diclofenac sodium salt at the concentration of 18.75 mg/mL, corresponding to a dosage unit amount of 75 mg, and thiocolchicoside at the concentration of 1 mg/mL, corresponding to a dosage unit amount of 4 mg.

The data set out in Table 1 prove the stability of a composition according to the invention containing diclofenac sodium salt, thiocolchicoside and BHA, compared with the same composition wherein BHA is replaced by the antioxidant sodium metabisulphite or N-acetylcysteine. Stability was monitored by HPLC analysis.
### Table 1

**Antioxidant in formula: Sodium metabisulphite**

<table>
<thead>
<tr>
<th>Time/Storage</th>
<th>Batch</th>
<th>Thiocol. content (%)</th>
<th>Diclof. content (%)</th>
<th>Thiocol. impurity (RRT=0.49. %)</th>
<th>Thiocol. impurity (RRT=0.54. %)</th>
<th>Thiocol. impurity (RRT=0.64. %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 month / 40°C</td>
<td>TFR12074B</td>
<td>89.8</td>
<td>93.6</td>
<td>2.93</td>
<td>0.33</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Antioxidant in formula: N-acetylcysteine**

<table>
<thead>
<tr>
<th>Time/Storage/Concentration</th>
<th>Batch</th>
<th>Thiocol. content (%)</th>
<th>Diclof. content (%)</th>
<th>Thiocol. impurity (RRT=0.49. %)</th>
<th>Thiocol. impurity (RRT=0.54. %)</th>
<th>Thiocol. impurity (RRT=0.64. %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 day/Ambient Temperature @ 0.5 mg mL⁻¹</td>
<td>TFR12195A</td>
<td>86.3</td>
<td>NA</td>
<td>NA</td>
<td>0.28</td>
<td>0.06</td>
</tr>
<tr>
<td>1 day/Ambient Temperature @30 mg mL⁻¹</td>
<td>TFR12195B</td>
<td>11.8</td>
<td>NA</td>
<td>69.50</td>
<td>0.33</td>
<td>1.04</td>
</tr>
</tbody>
</table>

**Antioxidant in formula: Butylated hydroxyanisole (BHA)**

<table>
<thead>
<tr>
<th>Time/Storage</th>
<th>Batch</th>
<th>Thiocol. content (%)</th>
<th>Diclof. content (%)</th>
<th>Thiocol. impurity (RRT=0.49. %)</th>
<th>Thiocol. impurity (RRT=0.54. %)</th>
<th>Thiocol. impurity (RRT=0.64. %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 month / 40°C</td>
<td>TFR12189A</td>
<td>99.25</td>
<td>98.27</td>
<td>ND</td>
<td>0.61</td>
<td>ND</td>
</tr>
</tbody>
</table>

NA = Not Analysed  
ND = Not Detectable  
RRT = Relative Retention Time
It will be observed that the presence of sodium metabisulphite or N-acetylcysteine causes the degradation of thiocolchicoside and, in the presence of sodium metabisulphite, which is the preferred antioxidant for injectable diclofenac, also of the latter active ingredient. Degradation is observed both under ambient storage conditions and at 40°C.

Conversely, the use of BHA enables the composition to maintain thiocolchicoside and diclofenac contents exceeding 99% and 98% respectively, even after one month’s storage at 40°C. Moreover, under these storage conditions two of the three impurities typically associated with the degradation of thiocolchicoside in solution are undetectable.

It has also surprisingly been found that the use of BHT (butylated hydroxytoluene, 2,6-bis(1,1-dimethylethyl)-4-methylphenol), an antioxidant which also has a phenol structure and is a close analogue of BHA, is unsuitable to guarantee the stability of a solution of diclofenac and thiocolchicoside, as it is associated with problems of poor solubility and precipitation under ordinary storage conditions.

The injectable composition according to the invention is suitable for intravenous, intramuscular or subcutaneous administration, and can be prepared by conventional methods well-known to the skilled person.

By way of example, Table 2 below shows the quantitative composition of a dosage unit (4 mL vial) according to the invention.

Table 2

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diclofenac sodium salt</td>
<td>75</td>
</tr>
<tr>
<td>Thiocolchicoside</td>
<td>4</td>
</tr>
<tr>
<td>Mannitol</td>
<td>6</td>
</tr>
<tr>
<td>Tert-butylhydroxyanisole</td>
<td>0.2</td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>1600</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>q.s. for pH 8.0-8.5</td>
</tr>
<tr>
<td>Purified water</td>
<td>q.s. for 4 mL</td>
</tr>
</tbody>
</table>

The composition reported in Table 2 represents a particularly preferred
embodiment of the invention.

A further aspect of the invention relates to the use of the composition according to the invention for the treatment of rheumatic or traumatic pain and inflammation of the joints, muscles, tendons and ligaments, in particular for the treatment of articular and extra-articular inflammatory rheumatological disorders, acute and chronic lumbosciatalgia, cervical neuralgia, torticollis and painful post-traumatic and post-operative syndromes.

The composition according to the invention can be administered in dosage unit amounts of 75 mg of diclofenac sodium and 4 mg of thiocolchicoside once or twice a day.

The invention will now be illustrated by the following example.

**Preparation of 1037.5 mL of injectable solution of diclofenac sodium salt and thiocolchicoside, corresponding to 250 vials**

**Preparation of the bulk solution**

According to the procedures the requested amount of Propylene Glycol (415 g) is poured into the dissolution tank, the stirring system is switched on and the component is heated up to 40 ± 5°C. The amount of Butylhydroxyanisole, 51.9 mg, is introduced into the dissolution tank and the preparation is stirred for 20 ± 10 minutes or until complete dissolution. Switch off the stirring system and verify the appearance of the solution: clear and colourless. Cool down to 25 ± 5°C, switch on the stirring system, then add the requested amount of water for injection (636.61 g) and Mannitol (1.6 g), then stir for 15 ± 5 minutes. Switch off the stirring system and verify the appearance of the solution: clear and colourless.

Switch on the stirring system, then load Diclofenac Sodium (19.5 g) and stir for 40 ± 10 minutes or until complete dissolution. Switch off the stirring system and verify the appearance of the solution: clear and colourless.

Switch on the stirring system, then load Thiocolchicoside (1.0375 g) and mix for 20 ± 5 minutes or until complete dissolution. Switch off the stirring system
and verify the appearance of the solution: clear yellow to amber solution.

Carry out the check of the density value (1.020 - 1.050 g/mL) and if necessary bring to weight with distilled water, then stir for about 10 minutes, switch off the stirring system and check again the appearance of the solution: clear yellow to amber solution.

Verify the pH value (7.0 - 9.0).

**Filtration of the solution**

The prepared solution is conveyed through a 0.22 µm disposable filter cartridge, from the dissolution vessel to a sterile stainless steel container. Keep the tank under N₂ pressure. Filter the solution, check the integrity of the filter before and after the filtration.

**Fillins of the ampoules**

The ampoules to be filled are previously depyrogenated and introduced in the filling room according to standard operating procedures. Equipment and filling parts are also cleaned and sterilized prior to use. Aseptic filling occurs in grade A environment with grade B background.

The tank, under N₂ pressure, filled up during step 3, is connected to the ampoule filling machine. The solution immediately prior to filling undergoes to a further 0.22 µm sterile filtration (Membrane: Nylon 6,6, covalently-modified positive Zeta/ Housing: Polypropylene). After the assembling of syringes, pistons, needles, tubes and filter, all the circuit is flushed with the solution to be filled and the desired volume (filling volume 4.15 ml*) is adjusted. The filling procedure starts and the ampoules are filled, hermetically sealed by fusion of the glass and collected in the steel trays. Before and at the end of the filling, check the integrity of the 0.22 µm sterile filter. The sealed ampoules are tested for integrity at the end of filling step.

* An overfill of 0.15 mL is applied to guarantee the minimum extractable volume of 4.0 mL.
CLAIMS

1. Pharmaceutical composition in the form of an injectable aqueous solution comprising diclofenac and thiocolchicoside or a pharmaceutically acceptable salt thereof as the active ingredients and tert-butylhydroxyanisole as stabilizer.

2. Composition according to claim 1, comprising diclofenac sodium salt.

3. Composition according to claims 1-2, wherein said aqueous solution consists of a mixture of water and propylene glycol.

4. Composition according to claims 1-3, further comprising an additional ingredient selected from local anaesthetic, solubilising agent, chelating agent, buffering agent and pH corrector.

5. Composition according to claims 1-4 comprising diclofenac sodium salt in amounts ranging from 25 to 75 mg per dosage unit.

6. Composition according to claim 5, wherein said amount is 75 mg.

7. Composition according to claims 1-6 comprising thiocolchicoside in amounts ranging from 1 to 10 mg per dosage unit.

8. Composition according to claim 7, wherein said amount is 4 mg.

9. Composition according to claims 1-8 comprising tert-butylhydroxyanisole in amounts ranging from 0.1 to 1.2 mg per dosage unit.

10. Composition according to claim 9, wherein said amount is 0.2 mg.

11. Composition according to claim 1, consisting of the following ingredients and amounts per dosage unit:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diclofenac sodium salt</td>
<td>75</td>
</tr>
<tr>
<td>Thiocolchicoside</td>
<td>4</td>
</tr>
<tr>
<td>Mannitol</td>
<td>6</td>
</tr>
<tr>
<td>tert-butylhydroxyanisole</td>
<td>0.2</td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>1600</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>q.s. for pH 8.0-8.5</td>
</tr>
<tr>
<td>Purified water</td>
<td>q.s. for 4 mL</td>
</tr>
</tbody>
</table>
12. Composition according to any one of the preceding claims, for use in the treatment of joint, muscle, tendon or ligament pain and inflammation of rheumatic or traumatic origin.
### A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K9/00  A61K9/08  A61K31/16  A61K31/196

According to International Patent Classification (IPC) into both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>FR 2 735 369 AI (SYNTHELABO [FR]) 20 December 1996 (1996-12-20) example 8</td>
<td>1-12</td>
</tr>
<tr>
<td>X</td>
<td>WO 2012/053012 A2 (CADI LA HEALTHCARE LTD [IN]; ROY SUNIL LENDU BHUSHAN [IN]; KOTHARI JAY SH) 26 April 1 2012 (2012-04-26) example 2</td>
<td>1-12</td>
</tr>
</tbody>
</table>

* Further documents are listed in the continuation of Box C.  

** Special categories of cited documents:  

A: document defining the general state of the art which is not considered to be of particular relevance  

E: earlier application or patent but published on or after the international filing date  

L*: document which may throw doubts on priority claim(s) one of which is cited to establish the publication date of another citation or other special reason (as specified)  

O*: document relating to an oral disclosure, use, exhibition or other means  

P*: document published prior to the international filing date but later than the priority date claimed  

T*: later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  

X*: document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  

Y*: document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  

S*: document member of the same patent family  

Date of the actual completion of the international search  

16 December 2013

Name and mailing address of the ISA/  

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Date of mailing of the international search report  

07/01/2014

Authorized officer  

Schi fferer, Hermann
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>FR 2735369</td>
<td>20-12-1996</td>
<td>AT 216246 T</td>
</tr>
<tr>
<td>DE 69620761</td>
<td>23-05-2002</td>
<td></td>
</tr>
<tr>
<td>ES 2175104</td>
<td>16-11-2002</td>
<td></td>
</tr>
<tr>
<td>FR 2735369</td>
<td>20-12-1996</td>
<td></td>
</tr>
<tr>
<td>PT 837684</td>
<td>30-09-2002</td>
<td></td>
</tr>
<tr>
<td>WO 9641635</td>
<td>27-12-1996</td>
<td></td>
</tr>
<tr>
<td>WO 2012053012</td>
<td>26-04-2012</td>
<td></td>
</tr>
</tbody>
</table>